Close

pCDCAR1 HIV1 h(ζ) (CAR-MZ210)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-HIV-1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target HIV-1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-HIV-1 antibody linked to CD3ζ signaling domains. And the vector product was designed for the treatment of HIV-1 infection.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • HIV-1
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • HIV-1 infection
  • Generation
  • First
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-CD3ζ
  • Discription of Signaling Cassetes
  • CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • 10E8
  • Host
  • Human
  • Target Species
  • Virus
  • Gene Name
  • Human immunodeficiency virus 1
  • Synonyms
  • HIV-1, Human immunodeficiency virus 1

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FCM

Fig.1  Proliferation mediated by novel CAR interactions with HIV-1-infected target cells.

CAR Construction : 10E8-41BB-CD3ζ Latest CAR Construction

Fig.1 Proliferation mediated by novel CAR interactions with HIV-1-infected target cells.

Primary CD8+ T lymphocytes transduced with CARs were enriched to>90% purity and labeled with CellTrace Violet and then cocultured with irradiated HIV-1 NL4-3-infected T2 cells.

Ali, A., Kitchen, S. G., Chen, I. S., Ng, H. L., Zack, J. A., & Yang, O. O. (2016). HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. Journal of virology, 90(15), 6999-7006.

Complete CAR data FuncS

Fig.2 Specific killing of HIV-1-infected target cells mediated by novel CARs.

CAR Construction : 10E8-41BB-CD3ζ Latest CAR Construction

Fig.2 Specific killing of HIV-1-infected target cells mediated by novel CARs.

CAR-transduced primary CD8+ T lymphocytes were cocultured with HIV-1-infected T2 cells in standard 4-h chromium release assays to assess killing mediated by the CARs.

Ali, A., Kitchen, S. G., Chen, I. S., Ng, H. L., Zack, J. A., & Yang, O. O. (2016). HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. Journal of virology, 90(15), 6999-7006.

Complete CAR data ELISA

Fig.3 Sample calculation of percent log efficiency of suppression by CAR-transduced cells.

CAR Construction : 10E8-41BB-CD3ζ Latest CAR Construction

Fig.3 Sample calculation of percent log efficiency of suppression by CAR-transduced cells.

T1-CCR5 cells were infected with the indicated viruses at a multiplicity of infection of 0.1 tissue culture infective doses cell and cultured with or without CAR 10E8-transduced CD8+ T cells (>90% enriched) at an effector-to-target cell ratio of 1:4.

Ali, A., Kitchen, S. G., Chen, I. S., Ng, H. L., Zack, J. A., & Yang, O. O. (2016). HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. Journal of virology, 90(15), 6999-7006.

CAR scFv data SPR

Fig.4 SPR for binding analysis.

CAR Construction : Latest CAR Construction

Fig.4 SPR for binding analysis.

Kinetic binding analysis revealed that the mature 10E8 binding to the HIV gp41 MPER peptide showed strong binding with decreasing off-rates.

Soto, C., Ofek, G., Joyce, M. G., Zhang, B., McKee, K., Longo, N. S., ... & Kwong, P. D. (2016). Developmental pathway of the MPER-directed HIV-1-neutralizing antibody 10E8. PloS one, 11(6), e0157409.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-HIV-1 (10E8) h(CD3ζ) CAR, pCDCAR1 (CAR-MZ210). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.